Category: Pharma News

The NIH discovers a novel autoinflammatory disease and suggests a target for potential treatments.

March 30, 2023
Scientists have discovered an autoinflammatory illness brought on by mutations in the LYN gene, a crucial immune response…

As part of risk-based inspections that were slated to take place in December of last year, pharmaceutical companies across the country were raided: CDSCO

March 30, 2023
According to senior CDSCO officials involved in the process, the risk-based inspections that the Central Drugs Standard Control…

To cure vascular and pigmented under-eye dark circles, Entod Beauty London introduces “Eyecirque Advance.”

March 29, 2023
In order to address pigmented and vascular under-eye dark circles, Entod Beauty London has recently introduced a unique…

MrMed releases a mobile app for easy access to cost-effective super-specialty medications.

March 29, 2023
The best online pharmacy in India for super-specialty drugs, MrMed, has announced the release of its mobile app.…

For an additional three months, the NPPA extends the TMR for five medical equipment, including oxygen concentrators

March 29, 2023
The cap on the trade margin for oxygen concentrators and five other medical devices that was imposed in…

DoP will shortly request additional funding from the finance ministry for the proposed PRIP scheme.

March 28, 2023
The Department of Pharmaceuticals (DoP) may approach the Ministry of Finance for additional funding for the proposed new…

Positive findings from the second interim analysis of the phase 2 randomised trial for BX1000 are reported by Baudax Bio.

March 28, 2023
The second preplanned interim analysis of Baudax Bio, Inc.’s phase 2 trial of BX1000 for neuromuscular blockade (NMB)…

As the Union government adds new conditions to the NPRD list, patient groups are awaiting clarification on the inclusion of rare diseases.

March 27, 2023
Patient advocacy groups are awaiting clarification on whether specific conditions will be covered by the National Policy of…

In an experimental research using the ROCK inhibitor NRL-1049 to treat cerebral cavernous malformations, Neurelis has started patient dosing.

March 27, 2023
The Rho kinase (ROCK) inhibitor NRL-1049, a potential treatment for people with cerebral cavernous malformations (CCM), a condition…
WhatsApp Telegram